scispace - formally typeset
N

Nora Pashayan

Researcher at University College London

Publications -  162
Citations -  6218

Nora Pashayan is an academic researcher from University College London. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 37, co-authored 144 publications receiving 4575 citations. Previous affiliations of Nora Pashayan include University of Melbourne & University College London Hospitals NHS Foundation Trust.

Papers
More filters
Journal ArticleDOI

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Fredrick R. Schumacher, +207 more
- 11 Jun 2018 - 
TL;DR: A large meta-analysis combining genome-wide and custom high-density genotyping array data identifies 63 new susceptibility loci for prostate cancer, enhancing fine-mapping efforts and providing insights into the underlying biology of PrCa1.
Journal ArticleDOI

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array

Rosalind A. Eeles, +156 more
- 01 Apr 2013 - 
TL;DR: In this paper, a custom Illumina array (iCOGS) was used to genotype 211,155 SNPs in blood DNA from 25,074 prostate cancer cases and 24,272 controls from the international PRACTICAL Consortium.
Journal ArticleDOI

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer

Ali Amin Al Olama, +179 more
- 01 Oct 2014 - 
TL;DR: These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.
Journal ArticleDOI

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

David V. Conti, +254 more
- 04 Jan 2021 - 
TL;DR: This paper conducted a meta-analysis of prostate cancer genome-wide association studies (107,247 cases and 127,006 controls) and identified 86 new genetic risk variants independently associated with prostate cancer risk, bringing the total to 269 known risk variants.
Journal ArticleDOI

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

TL;DR: Not offering breast cancer screening to women at lower risk could improve the cost-effectiveness of the screening program, reduce overdiagnosis, and maintain the benefits of screening.